Updated on 26 August 2026
Nanomedicine for Drug Delivery, Imaging and Theranostics
Senior Scientist at Regional Institute of Oncology, Iasi
Iasi, Romania
About
Expertise offered:
IRO-TRANSCEND is a multidisciplinary cancer research centre combining cancer biology, biomarker discovery and nanomedicine. Our Nanotechnology Laboratory develops and investigates liposomes, microemulsions, magnetic nanoparticles and layered double hydroxides for drug delivery, contrast agents and theranostic applications.
Expertise sought:
We are looking for academic, clinical and industrial partners with complementary expertise in nanomedicine, drug delivery, cancer biomarkers, molecular imaging, pharmacology, preclinical models and translational research. We are also interested in partners with computational and AI expertise who could support specific aspects of nanocarrier design, nano–bio interactions, protein corona formation, drug delivery and prediction of treatment response.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Similar opportunities
Project cooperation
The Centre for Innovative Medicine (IMC)
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Tatjana Ivaskiene
General manager at State Research Institute Centre for Innovative Medicine
Vilnius, Lithuania
Project cooperation
The Centre for Innovative Medicine (IMC)
- Partner seeks Consortium/Coordinator
- Consortium/Coordinator seeks Partners
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
Tatjana Ivaskiene
General manager at State Research Institute Centre for Innovative Medicine
Vilnius, Lithuania
Project cooperation
Human-Centred Oversight for Trustworthy AI in Health and Cancer Care
- Partner seeks Consortium/Coordinator
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
- Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
- Digital health and AI: HORIZON-HLTH-2027-03-TOOL-04 Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
Bram Lievens
Research Valorisation Manager at IMEC-SMIT, Vrije Universiteit Brussel
Brussels, Belgium